{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T04:14:22Z","timestamp":1690690462759},"reference-count":34,"publisher":"South African Medical Association NPC","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Afr J Crit Care"],"abstract":"<jats:p>&#x0D;\n&#x0D;\n&#x0D;\n&#x0D;\nBackground. There are limited data on the clinical characteristics and outcomes of patients with myasthenia gravis (MG) admitted to the intensive care unit (ICU) at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH).&#x0D;\nObjectives. The aim was to study the clinical characteristics and outcomes of patients with MG admitted to the CMJAH over two decades.&#x0D;\nMethods. A retrospective study was undertaken of patients with MG admitted to the multidisciplinary ICU of CMJAH over a 20-year period, from 1998 to 2017. Demographic data, clinical features, management and outcomes of patients were assessed and reviewed from the case records.&#x0D;\nResults. Thirty-four patients with MG were admitted to the ICU during this period: 24 female and 10 male. The mean age \u00b1 SD was 37.4 \u00b1 13.0 years, with a range of 16 - 66 years. Four patients were human immunodeficiency virus (HIV)-positive. The mean length of stay (LOS) in ICU was 10.6 \u00b1 20.1 days, ranging from 1 to 115 days. Two patients were diagnosed with MG in the ICU after failure to wean from the ventilator. Overall, 22 patients were intubated and ventilated on admission. Morbidities included self-extubation, aspiration pneumonia and iatrogenic pneumothorax. History of thymectomy was present in 12 patients. The treatments received for MG included pyridostigmine (73.5%), corticosteroids (55.9%), azathioprine (35.3%), plasmapheresis (26.5%) and intravenous immunoglobulin (8.8%). The overall mortality in the ICU was 5.9%.&#x0D;\nConclusion. MG is a serious disorder with considerable morbidity and mortality. It is, however, a potentially manageable disease, provided that appropriate ICU resources are available.&#x0D;\n&#x0D;\n&#x0D;\n&#x0D;\n<\/jats:p>","DOI":"10.7196\/sajcc.2023.v39i2.561","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T13:37:18Z","timestamp":1690637838000},"page":"36-40","source":"Crossref","is-referenced-by-count":0,"title":["Clinical features and outcomes of patients with myasthenia gravis admitted to an intensive care unit: A 20-year retrospective study"],"prefix":"10.7196","author":[{"given":"R","family":"Morar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GEMP","family":"Group 6-2018","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Seedat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G A","family":"Rchards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4425","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"20395","doi-asserted-by":"crossref","unstructured":"Gilhus NE. Myasthenia Gravis. N Engl J Med 2016;375(26):2570-2581. https:\/\/doi.org\/10.1056\/ NEJMra1602678","DOI":"10.1056\/NEJMra1602678"},{"key":"20396","doi-asserted-by":"crossref","unstructured":"Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009;72(18):1548-1554. https:\/\/ doi.org\/10.1212\/WNL.0b013e3181a41211","DOI":"10.1212\/WNL.0b013e3181a41211"},{"key":"20397","doi-asserted-by":"crossref","unstructured":"JuelVC.Myastheniagravis:Managementofmyastheniccrisisandperioperativecare.SeminNeurol 2004;24(1):75-81. https:\/\/doi.org\/10.1055\/s-2004-829595","DOI":"10.1055\/s-2004-829595"},{"key":"20398","doi-asserted-by":"crossref","unstructured":"Ling C-S, Shen M-L, Wang Y, et al. The associations of HLA-DRB1 gene polymorphisms with late- onset myasthenia gravis: A meta-analysis. Neurol Sci 2020;41(5):1041-1049. https:\/\/doi.org\/10.1007\/ s10072-019-04213-7","DOI":"10.1007\/s10072-019-04213-7"},{"key":"20399","doi-asserted-by":"crossref","unstructured":"Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S. The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve 2021;64(2):212-215. https:\/\/doi. org\/10.1002\/mus.27326","DOI":"10.1002\/mus.27326"},{"key":"20400","doi-asserted-by":"crossref","unstructured":"Huan X, Zhao R, Song J, et al. Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis. BMC Immunol 2022;23(1):26. https:\/\/doi.org\/10.1186\/ s12865-022-00501-8","DOI":"10.1186\/s12865-022-00501-8"},{"key":"20401","doi-asserted-by":"crossref","unstructured":"Boldingh MI, Dekker L, Maniaol AH, et al. An up-date on health-related quality of life in myasthenia gravis - results from population based cohorts. Health Qual Life Outcomes 2015;13:115. https:\/\/doi.org\/10.1186\/s12955-015-0298-1","DOI":"10.1186\/s12955-015-0298-1"},{"key":"20402","doi-asserted-by":"crossref","unstructured":"BedlackRS,SandersDB.Ontheconceptofmyastheniccrisis.JClinNeuromusculDis2002;4(1):40- 42. https:\/\/doi.org\/10.1097\/00131402-200209000-00009","DOI":"10.1097\/00131402-200209000-00009"},{"key":"20403","doi-asserted-by":"crossref","unstructured":"Neumann B, Angstwurm K, Mergenthaler P, et al. Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases. Neurology 2020;94(3):e299-e313. https:\/\/doi. org\/10.1212\/WNL.0000000000008688","DOI":"10.1212\/WNL.0000000000008688"},{"key":"20404","doi-asserted-by":"crossref","unstructured":"ThomasCE,MayerSA,GungorY,etal.Myastheniccrisis:clinicalfeatures,mortality,complications, and risk factors for prolonged intubation. Neurology 1997;48(5):1253-1260. https:\/\/doi.org\/10.1212\/ wnl.48.5.1253","DOI":"10.1212\/WNL.48.5.1253"},{"key":"20405","doi-asserted-by":"crossref","unstructured":"Spillane J, Hirsch NP, Kullmann DM, Taylor C, Howard RS. Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis. Eur J Neurol 2014;21(1):171-173. https:\/\/doi.org\/10.1111\/ene.12115","DOI":"10.1111\/ene.12115"},{"key":"20406","doi-asserted-by":"crossref","unstructured":"Ramos-Fransi A, Rojas-Garc\u00eda R, Segovia S, et al. Myasthenia gravis: Descriptive analysis of life- threatening events in a recent nationwide registry. Eur J Neurol 2015;22(7):1056-1061. https:\/\/doi. org\/10.1111\/ene.12703","DOI":"10.1111\/ene.12703"},{"key":"20407","doi-asserted-by":"crossref","unstructured":"O\u2019Riordan JI, Miller DH, Mottershead JP, Hirsch NP, Howard RS. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol 1998;5(2):137-142. https:\/\/doi.org\/10.1046\/j.1468-1331.1998.520137.x","DOI":"10.1046\/j.1468-1331.1998.520137.x"},{"key":"20408","doi-asserted-by":"crossref","unstructured":"KalitaJ,KohatAK,MisraUK.Predictorsofoutcomeofmyastheniccrisis.NeurolSci2014;35(7):1109- 1114. https:\/\/doi.org\/10.1007\/s10072-014-1659-y","DOI":"10.1007\/s10072-014-1659-y"},{"key":"20409","doi-asserted-by":"crossref","unstructured":"Werneck LC, Scola RH, Germiniani FMB, Comerlato EA, Cunha FMB. Myasthenic crisis: Report of 24 cases. Arq Neuropsiquiatr 2002;60(3-A):519-526. https:\/\/doi.org\/10.1590\/s0004- 282x2002000400001","DOI":"10.1590\/S0004-282X2002000400001"},{"key":"20410","doi-asserted-by":"crossref","unstructured":"Damian MS, Ben-Shlomo Y, Howard R, et al. The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barr\u00e9 syndrome admitted to critical care : An analysis of the Intensive Care National Audit & Research Centre (ICNARC) national United Kingdom database. Intensive Care Med 2013;39(8):1405-1412. https:\/\/doi.org\/10.1007\/s00134-013-2960-6","DOI":"10.1007\/s00134-013-2960-6"},{"key":"20411","doi-asserted-by":"crossref","unstructured":"Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med 1997;25(7):1228-1235. https:\/\/doi.org\/10.1097\/00003246-199707000-00027","DOI":"10.1097\/00003246-199707000-00027"},{"key":"20412","doi-asserted-by":"crossref","unstructured":"Murthy JMK, Meena AK, Chowdary GVS, Naryanan JT. Myasthenic crisis: Clinical features, complications and mortality. Neurol India 2005;53(1):37-40; discussion 40. https:\/\/doi. org\/10.4103\/0028-3886.15050","DOI":"10.4103\/0028-3886.15050"},{"key":"20413","doi-asserted-by":"crossref","unstructured":"LiuC,WangQ,QiuZ,etal.Analysisofmortalityandrelatedfactorsin2195adultmyastheniagravis patients in a 10-year follow-up study. Neurol India 2017;65(3):518-524. https:\/\/doi.org\/10.4103\/ neuroindia.NI_804_16","DOI":"10.4103\/neuroindia.NI_804_16"},{"key":"20414","doi-asserted-by":"crossref","unstructured":"Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia gravis: A review of available treatment approaches. Autoimmune Dis 2011;2011:847393. https:\/\/doi.org\/10.4061\/2011\/847393 21. Onyekwulu FA, Onwuekwe IO. Critical care of myasthenia gravis in a resource poor setting:","DOI":"10.4061\/2011\/847393"},{"key":"20415","doi-asserted-by":"crossref","unstructured":"A study of South East Nigeria. Neurologist 2010;16(6):368-370. https:\/\/doi.org\/10.1097\/","DOI":"10.1097\/NRL.0b013e3181c29f25"},{"key":"20416","unstructured":"NRL.0b013e3181c29f25"},{"key":"20417","unstructured":"OssermanKE,GenkinsG.Studiesinmyastheniagravis:Reviewofatwenty-yearexperienceinover 1200 patients. Mt Sinai J Med 1971;38(6):497-537."},{"key":"20418","doi-asserted-by":"crossref","unstructured":"Al-Bassam W, Kubicki M, Bailey M, et al. Characteristics, incidence, and outcome of patients admitted to the intensive care unit with myasthenia gravis. J Crit Care 2018;45:90-94. https:\/\/doi. org\/10.1016\/j.jcrc.2018.01.003","DOI":"10.1016\/j.jcrc.2018.01.003"},{"key":"20419","doi-asserted-by":"crossref","unstructured":"Misra UK, Kumar S, Singh VK, Dubey D, Kalita J. Noninvasive ventilation in myasthenia gravis. Neurol India 2020;68(3):648-651. https:\/\/doi.org\/10.4103\/0028-3886.289001","DOI":"10.4103\/0028-3886.289001"},{"key":"20420","doi-asserted-by":"crossref","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010;10:46. https:\/\/doi.org\/10.1186\/1471- 2377-10-46","DOI":"10.1186\/1471-2377-10-46"},{"key":"20421","doi-asserted-by":"crossref","unstructured":"Mombaur B, Lesosky MR, Liebenberg L, Vreede H, Heckmann JM. Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa. Muscle Nerve 2015;51(4):533-537. https:\/\/doi.org\/10.1002\/mus.24348","DOI":"10.1002\/mus.24348"},{"key":"20422","doi-asserted-by":"crossref","unstructured":"Al-Bassam W, Kubicki M, Bailey M, et al. Characteristics, incidence, and outcome of patients admitted to the intensive care unit with myasthenia gravis. J Crit Care 2018;45:90-94. https:\/\/doi. org\/10.1016\/j.jcrc.2018.01.003","DOI":"10.1016\/j.jcrc.2018.01.003"},{"key":"20423","doi-asserted-by":"crossref","unstructured":"Paul E, Bailey M, Pilcher D. Risk prediction of hospital mortality for adult patients admitted to Australian and New Zealand intensive care units: Development and validation of the Australian and New Zealand Risk of Death model. J Crit Care 2013;28(6):935-941. https:\/\/doi.org\/10.1016\/j. jcrc.2013.07.058","DOI":"10.1016\/j.jcrc.2013.07.058"},{"key":"20424","doi-asserted-by":"crossref","unstructured":"Berrih-Aknin S, Le Panse R. Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 2014;52:90-100. https:\/\/doi.org\/10.1016\/j. jaut.2013.12.011","DOI":"10.1016\/j.jaut.2013.12.011"},{"key":"20425","doi-asserted-by":"crossref","unstructured":"Spillane J, Higham E, Kullmann DM. Myasthenia gravis. BMJ 2012;345:e8497. https:\/\/doi. org\/10.1136\/bmj.e8497","DOI":"10.1136\/bmj.e8497"},{"key":"20426","doi-asserted-by":"crossref","unstructured":"Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev 2021;20(1):102712. https:\/\/doi.org\/10.1016\/j.autrev.2020.102712","DOI":"10.1016\/j.autrev.2020.102712"},{"key":"20427","doi-asserted-by":"crossref","unstructured":"Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82(6):671-673. https:\/\/ doi.org\/10.1136\/jnnp.2009.197632","DOI":"10.1136\/jnnp.2009.197632"},{"key":"20428","doi-asserted-by":"crossref","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011;76(23):2017-2023. https:\/\/doi.org\/10.1212\/ WNL.0b013e31821e5505","DOI":"10.1212\/WNL.0b013e31821e5505"}],"container-title":["Southern African Journal of Critical Care"],"original-title":[],"link":[{"URL":"https:\/\/samajournals.co.za\/index.php\/sajcc\/article\/download\/1320\/551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/samajournals.co.za\/index.php\/sajcc\/article\/download\/1320\/551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T13:37:33Z","timestamp":1690637853000},"score":1,"resource":{"primary":{"URL":"https:\/\/samajournals.co.za\/index.php\/sajcc\/article\/view\/1320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7196\/sajcc.2023.v39i2.561","relation":{},"ISSN":["2078-676X","1562-8264"],"issn-type":[{"value":"2078-676X","type":"electronic"},{"value":"1562-8264","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}